company background image
OBSE.F logo

ObsEva OTCPK:OBSE.F Stock Report

Last Price

US$0.013

Market Cap

US$1.7m

7D

0%

1Y

-87.5%

Updated

28 Mar, 2024

Data

Company Financials

OBSE.F Stock Overview

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health.

OBSE.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

ObsEva SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ObsEva
Historical stock prices
Current Share PriceCHF0.013
52 Week HighCHF0.40
52 Week LowCHF0.000001
Beta0.63
1 Month Change-82.14%
3 Month Change-64.29%
1 Year Change-87.50%
3 Year Change-99.63%
5 Year Change-99.91%
Change since IPO-99.89%

Recent News & Updates

Recent updates

ObsEva stock dips on Nasdaq non-compliance notice

Aug 22

ObsEva to retire $31M in debt and announces $11M debt refinancing

Aug 01

ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress

Jul 05

Shareholder Returns

OBSE.FUS BiotechsUS Market
7D0%0.9%0.2%
1Y-87.5%11.0%28.1%

Return vs Industry: OBSE.F underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: OBSE.F underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is OBSE.F's price volatile compared to industry and market?
OBSE.F volatility
OBSE.F Average Weekly Movement363,860.1%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: OBSE.F's share price has been volatile over the past 3 months.

Volatility Over Time: OBSE.F's weekly volatility has decreased from 794339% to 363860% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201215Fabien de Ladonchampshttps://www.obseva.com

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

ObsEva SA Fundamentals Summary

How do ObsEva's earnings and revenue compare to its market cap?
OBSE.F fundamental statistics
Market capUS$1.69m
Earnings (TTM)US$7.92m
Revenue (TTM)US$19.64m

0.2x

P/E Ratio

0.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OBSE.F income statement (TTM)
RevenueUS$19.64m
Cost of RevenueUS$10.71m
Gross ProfitUS$8.93m
Other ExpensesUS$1.01m
EarningsUS$7.92m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)0.068
Gross Margin45.46%
Net Profit Margin40.34%
Debt/Equity Ratio0%

How did OBSE.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.